about
Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Targeting glioma stem-like cell survival and chemo-resistance through inhibition of lysine-specific histone demethylase KDM2B.Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.The siren song of bevacizumab: swan song or clarion call?Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis.Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.Treatment of glioblastoma in adultsImaging biomarkers guided anti-angiogenic therapy for malignant gliomasVEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenanceRescue of 2-Deoxyglucose Side Effects by Ketogenic Diet
P2860
Q47773621-BDF05C92-356C-4151-85D8-A356C9560898Q47845301-37FE7310-0EA2-4147-8E06-22A0F61E901FQ48299999-5ADE8289-75F8-4B0D-9B01-2445E2F484BBQ49818975-36839D99-F214-4417-923F-E934FCDBBDB6Q50057597-D956441A-C8B3-4E41-BC97-79F4DCA11E09Q50069174-E33F5F25-D043-4D3B-8C61-2190824035C1Q53829808-0D4D3CB6-4E96-494C-9CDE-F9931BCB1B31Q55386847-5DFAA655-C901-4713-8793-6E314CC0680EQ55457289-426259ED-FAFE-41E3-BE51-AB4CAE4DC0C0Q57174802-7DCDAC89-0FA8-4495-B512-EDF7C6E5C641Q57177114-45E91A05-9CDE-4FE4-BB82-CBCE09E26346Q57291646-3B68A3DE-CB71-409F-A98D-2068310E6C36Q58734114-47E21E85-BB42-4905-9B3B-2E25A56AA8A3
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Lomustine and Bevacizumab in Progressive Glioblastoma.
@en
Lomustine and Bevacizumab in Progressive Glioblastoma.
@nl
type
label
Lomustine and Bevacizumab in Progressive Glioblastoma.
@en
Lomustine and Bevacizumab in Progressive Glioblastoma.
@nl
prefLabel
Lomustine and Bevacizumab in Progressive Glioblastoma.
@en
Lomustine and Bevacizumab in Progressive Glioblastoma.
@nl
P2093
P50
P356
P1476
Lomustine and Bevacizumab in Progressive Glioblastoma.
@en
P2093
Alba A Brandes
Francois Dubois
Inga Harting
Jacoline C Bromberg
Julien Domont
Mario Campone
Martin J van den Bent
Martin Klein
Martin Taphoorn
Michael Platten
P304
P356
10.1056/NEJMOA1707358
P407
P50
P577
2017-11-01T00:00:00Z